WO2016184577A3 - Composition de poudre sèche comprenant de l'arn à chaîne longu - Google Patents

Composition de poudre sèche comprenant de l'arn à chaîne longu Download PDF

Info

Publication number
WO2016184577A3
WO2016184577A3 PCT/EP2016/000846 EP2016000846W WO2016184577A3 WO 2016184577 A3 WO2016184577 A3 WO 2016184577A3 EP 2016000846 W EP2016000846 W EP 2016000846W WO 2016184577 A3 WO2016184577 A3 WO 2016184577A3
Authority
WO
WIPO (PCT)
Prior art keywords
long
dry powder
powder composition
chain rna
rna molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/000846
Other languages
English (en)
Other versions
WO2016184577A2 (fr
Inventor
Benyamin YAZDAN PANAH
Fabian Johannes EBER
Stefanie SEWING
Thomas Ketterer
Thorsten Mutzke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curevac SE
Original Assignee
Curevac AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac AG filed Critical Curevac AG
Priority to EP16728216.9A priority Critical patent/EP3298143A2/fr
Publication of WO2016184577A2 publication Critical patent/WO2016184577A2/fr
Publication of WO2016184577A3 publication Critical patent/WO2016184577A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une formulation d'ARN à chaîne longue stable au stockage. En particulier, l'invention concerne une composition de poudre sèche comprenant une molécule d'ARN à chaîne longue. La présente invention concerne en outre des procédés de préparation d'une composition de poudre sèche comprenant une molécule d'ARN à chaîne longue par séchage par atomisation ou pulvérisation-cryodessiccation. L'invention concerne en outre l'utilisation de ladite composition de poudre sèche comprenant une molécule d'ARN à chaîne longue dans la préparation de compositions pharmaceutiques et de vaccins, un procédé de traitement ou de prévention d'un trouble ou d'une maladie, une première et une seconde utilisations médicales de ladite composition de poudre sèche comprenant une molécule d'ARN à chaîne longue et des kits, en particulier des kits de parties, comprenant ladite composition de poudre sèche comprenant une molécule d'ARN à chaîne longue.
PCT/EP2016/000846 2015-05-20 2016-05-20 Composition de poudre sèche comprenant de l'arn à chaîne longu Ceased WO2016184577A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16728216.9A EP3298143A2 (fr) 2015-05-20 2016-05-20 Composition de poudre sèche comprenant de l'arn à chaîne longu

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15001517 2015-05-20
EP15001517.0 2015-05-20

Publications (2)

Publication Number Publication Date
WO2016184577A2 WO2016184577A2 (fr) 2016-11-24
WO2016184577A3 true WO2016184577A3 (fr) 2017-01-12

Family

ID=53275951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/000846 Ceased WO2016184577A2 (fr) 2015-05-20 2016-05-20 Composition de poudre sèche comprenant de l'arn à chaîne longu

Country Status (2)

Country Link
EP (1) EP3298143A2 (fr)
WO (1) WO2016184577A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2795110T3 (es) 2011-06-08 2020-11-20 Translate Bio Inc Lípidos escindibles
WO2017191274A2 (fr) 2016-05-04 2017-11-09 Curevac Ag Arn codant pour une protéine thérapeutique
EP4631970A3 (fr) 2016-05-04 2026-01-07 CureVac SE Molécules d'acide nucléique et leurs utilisations
WO2018115527A2 (fr) 2016-12-23 2018-06-28 Curevac Ag Vaccin contre le coronavirus du syndrome respiratoire du moyen-orient
US11464847B2 (en) 2016-12-23 2022-10-11 Curevac Ag Lassa virus vaccine
CN111511928A (zh) 2017-12-21 2020-08-07 库瑞瓦格股份公司 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172430A1 (en) * 2006-01-20 2007-07-26 Nastech Pharmaceutical Company Inc. Dry powder compositions for rna influenza therapeutics
WO2011069529A1 (fr) * 2009-12-09 2011-06-16 Curevac Gmbh Solution contenant du mannose pour la lyophilisation, la transfection et/ou l'injection d'acides nucléiques
WO2011069528A1 (fr) * 2009-12-09 2011-06-16 Curevac Gmbh Lyophilisation d'acides nucléiques dans des solutions contenant du lactate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002101412A2 (fr) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Compositions lyophilisees de pulverisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172430A1 (en) * 2006-01-20 2007-07-26 Nastech Pharmaceutical Company Inc. Dry powder compositions for rna influenza therapeutics
WO2011069529A1 (fr) * 2009-12-09 2011-06-16 Curevac Gmbh Solution contenant du mannose pour la lyophilisation, la transfection et/ou l'injection d'acides nucléiques
WO2011069528A1 (fr) * 2009-12-09 2011-06-16 Curevac Gmbh Lyophilisation d'acides nucléiques dans des solutions contenant du lactate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JENSEN D M K ET AL: "Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 142, no. 1, 25 February 2010 (2010-02-25), pages 138 - 145, XP026892483, ISSN: 0168-3659, [retrieved on 20091022], DOI: 10.1016/J.JCONREL.2009.10.010 *

Also Published As

Publication number Publication date
EP3298143A2 (fr) 2018-03-28
WO2016184577A2 (fr) 2016-11-24

Similar Documents

Publication Publication Date Title
EP3916091A3 (fr) Composition de poudre sèche comprenant de l'arn à longue chaîne
WO2016184576A3 (fr) Composition de poudre sèche comprenant de l'arn à chaîne longue
WO2016184577A3 (fr) Composition de poudre sèche comprenant de l'arn à chaîne longu
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
BR112019024747A2 (pt) formulações de dose fixa
WO2018089851A3 (fr) Vaccin antigrippal
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
WO2017070616A3 (fr) Vaccins contre les maladies sexuellement transmissibles
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
ZA201900367B (en) Formulation of a peptide vaccine
WO2017070620A3 (fr) Vaccin contre le virus de la grippe à large spectre
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
WO2017070626A3 (fr) Vaccins contre les virus respiratoires
WO2015018380A3 (fr) Nanoparticules thérapeutiques et leurs procédés de préparation
BR112013005679A2 (pt) imidazopiridazinas substituídas
WO2015160843A8 (fr) Activateurs des canaux ioniques et leurs procédés d'utilisation
ZA202310755B (en) Immunogenic composition against influenza
BR112015022095A8 (pt) composição farmacêutica, método de fabricação, composição eutética e uso de composições contendo hcl ciclobenzabrina e manitol
HK1247856A1 (zh) 羟丙基β-环糊精组合物及方法
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
WO2014131739A3 (fr) Composés imidazopyridazines substitués
WO2015033302A3 (fr) Compositions de fulvestrant
BR112014020930A2 (pt) método para produzir uma formulação seca de um agente biofármaco, e, formulação de um agente biofármaco
BR112017009510A2 (pt) composições compreendendo ciclosporina
WO2015081319A3 (fr) Compositions de curcumine à activité améliorée et méthodes d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16728216

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2016728216

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE